Literature DB >> 29075060

Pantoprazole Induces Apoptosis of Leukemic Cells by Inhibiting Expression of P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through PI3K/AKT/mTOR Signaling.

Miao Liu1, Rong Tang1, Yi Jiang1.   

Abstract

This study aims to investigate the effects and mechanism of pantoprazole on multidrug resistant leukemia K562/A02 and K562/ADM cell lines. K562/A02 and K562/ADM cells at logarithmic growth phase were pre-treated with different concentration of pantoprazole (0, 50, 100, 200 μg/mL) for 24 h. Flow cytometry was used to measure the cell growth cycle and apoptosis. RT-PCR and Western blot were used to measure the expression of p-PI3K, p-AKT, p-mTOR, P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MRP1). Pantoprazole pretreatment significantly increased the ratio of G0/G1 phase but decreased the S phase of K562/A02 and K562/ADM cells in dose-dependent manner (p < 0.05). Flow cytometry analysis indicated that pretreatment of leukemic cells with pantoprazole induced apoptosis in a dose-dependent manner. RT-PCR and Western blot analysis indicated that pantoprazole pretreatment inhibited the mRNA and protein expression of p-PI3K, p-Akt, p-mTOR, P-gp and MRP1 in K562/A02 and K562/ADM cells in a dose-dependent manner (p < 0.05). Pantoprazole arrested cell cycle and induced apoptosis of multidrug resistant leukemic cells by inhibiting the expression of P-gp and MRP1 through PI3K/Akt/mTOR signaling pathway.

Entities:  

Keywords:  Leukemia; Multidrug resistance-associated protein-1; P-glycoprotein; PI3K/AKT/mTOR signaling; Pantoprazole; Proton pump inhibitor

Year:  2017        PMID: 29075060      PMCID: PMC5640553          DOI: 10.1007/s12288-017-0808-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  25 in total

1.  Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice.

Authors:  Sagar Agarwal; Yasuo Uchida; Rajendar K Mittapalli; Ramola Sane; Tetsuya Terasaki; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2012-03-08       Impact factor: 3.922

2.  Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.

Authors:  Huizhe Wu; Hui Kang; Yong Liu; Weiwei Tong; Duo Liu; Xiuli Yang; Minqiong Lian; Weifan Yao; Haishan Zhao; Desheng Huang; Xianzheng Sha; Enhua Wang; Minjie Wei
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-19       Impact factor: 4.553

Review 3.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 4.  Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

Authors:  A M Martelli; C Evangelisti; W Chappell; S L Abrams; J Bäsecke; F Stivala; M Donia; P Fagone; F Nicoletti; M Libra; V Ruvolo; P Ruvolo; C R Kempf; L S Steelman; J A McCubrey
Journal:  Leukemia       Date:  2011-03-25       Impact factor: 11.528

5.  Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

Authors:  Ali R Jazirehi; Mario I Vega; Devasis Chatterjee; Lee Goodglick; Benjamin Bonavida
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

6.  Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.

Authors:  Ramola Sane; Sagar Agarwal; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2013-02-08       Impact factor: 4.030

Review 7.  MRP1 and its role in anticancer drug resistance.

Authors:  Jamie F Lu; Deep Pokharel; Mary Bebawy
Journal:  Drug Metab Rev       Date:  2015-11-05       Impact factor: 4.518

Review 8.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

9.  Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase.

Authors:  Xiaoyu Zeng; Lin Liu; Mengzhu Zheng; Huimin Sun; Juanjuan Xiao; Tao Lu; Guangqian Huang; Pianpian Chen; Jianmin Zhang; Feng Zhu; Hua Li; Qiuhong Duan
Journal:  Oncotarget       Date:  2016-04-19

10.  Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.

Authors:  Timon Vandamme; Matthias Beyens; Ken Op de Beeck; Fadime Dogan; Peter M van Koetsveld; Patrick Pauwels; Geert Mortier; Christel Vangestel; Wouter de Herder; Guy Van Camp; Marc Peeters; Leo J Hofland
Journal:  Br J Cancer       Date:  2016-03-15       Impact factor: 7.640

View more
  3 in total

1.  Expression of multidrug-resistance associated proteins in human retinoblastoma treated by primary enucleation.

Authors:  Li-Juan Tang; Li-Jun Zhou; Wen-Xin Zhang; Jian-Yan Lin; Yong-Ping Li; Hua-Sheng Yang; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

Review 2.  Proton pump inhibitors and sensitization of cancer cells to radiation therapy.

Authors:  Kassidy A Hebert; Mark D Bonnen; Yohannes T Ghebre
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

3.  The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting BIRC5 to Elucidate the Synergistic Pathway of Survivin with P-Glycoprotein in Cancer Multi-Drug Resistance.

Authors:  Changping Deng; Fabiao Hu; Zhangting Zhao; Yiwen Zhou; Yuping Liu; Tong Zhang; Shihui Li; Wenyun Zheng; Wenliang Zhang; Tianwen Wang; Xingyuan Ma
Journal:  Front Cell Dev Biol       Date:  2022-01-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.